尼沃卢马布剂量升级后1型糖尿病的发展:一个病例报告
Sayaka Mabuchi1,2, Naoko Adachi2, Atsushi Nagasawa2
1Department of Human Resources Development for General Practitioner, Shimane Prefectural Central Hospital, Izumo, Japan.
Medicine
|July 23, 2025
概括
高剂量的尼沃卢马布可能会增加免疫检查点抑制剂诱导的1型糖尿病 (ICI-T1DM) 的风险,特别是在体重较低的患者中. 剂量优化可以减轻这种风险,同时保持治疗疗效.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
背景情况:
- 免疫检查点抑制剂诱导的1型糖尿病 (ICI-T1DM) 是一种罕见但严重的不良事件,与编程细胞死亡-1抑制剂如nivolumab相关.
- 尼沃卢马布剂量与ICI-T1DM发病之间的关系尚未得到充分证实.
- 这项研究调查了尼沃卢马布剂量升级后的ICI-T1DM病例.
研究的目的:
- 在患有晚期食道癌症的患者中报告ICI-T1DM病例.
- 探索尼沃卢马布剂量增加与ICI-T1DM发展之间的潜在联系.
- 审查关于ICI-T1DM和尼沃卢马布治疗的现有文献.
主要方法:
- 一名患有晚期食道癌症的患者接受了尼沃卢马布治疗超过两年.
- 尼沃卢马布的剂量从每14天增加240毫克增加到每28天增加480毫克.
- 患者在剂量增加96天后出现了高血糖和糖尿病酸性脂肪酸症的症状.
主要成果:
- 这名患者被诊断为尼沃卢马布诱导的发性1型糖尿病,其特征是高血糖和低C水平.
- 该案例表明,较高的尼沃卢马布剂量与ICI-T1DM风险增加之间存在潜在的关联.
- 在体重较低的人群中,这种风险可能更明显.
结论:
- 优化尼沃卢马布的剂量可能是减少ICI-T1DM发病率的一种策略.
- 保持治疗疗效,同时尽量减少与免疫相关的不良事件至关重要.
- 需要进一步的研究才能充分理解ICI-T1DM中剂量反应关系.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
3.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.3K
Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
Insulin: Dosing Regimen and Adverse Effects
262
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
262
Diabetes: Symptoms, Diagnosis, and Complications
697
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
697
Psychoneuroimmunology: Diabetes and Cancer
62
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
62
Diabetes: Management and Pharmacotherapy
399
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
399


